Comparing the current results to its competitors, Blueprint Medicines reported Revenue increase in the 1 quarter 2025 by 55.45 % year on year. The sales growth was above Blueprint Medicines's competitors' average revenue growth of 21.02 %, achieved in the same quarter.
Blueprint Medicines's Comment on Competition and Industry Peers
The company operates in the pharmaceutical and biotechnology industries, focusing on the development of kinase inhibitors and targeted protein degraders in the allergy/inflammation and oncology/hematology sectors. It faces competition from major pharmaceutical, specialty pharmaceutical, and biotechnology companies, as well as academic institutions, governmental agencies, and public and private research institutions globally. Competitors include divisions of large pharmaceutical companies and biotechnology firms of various sizes, many with greater financial resources and expertise in research and development, manufacturing, clinical trials, regulatory approvals, and marketing. Industry consolidation through mergers and acquisitions may concentrate resources among fewer competitors. Additionally, smaller or early-stage companies can be significant competitors, particularly through collaborations with larger companies.
Due to outstanding performance in Overall company, revenue grew by 55.45 % Blueprint Medicines Corporation improved its market share, to approximately 1.59 %.
Publicly Traded Peers of Blueprint Medicines Corporation
Kura Oncology Inc Share Performance
+3.20%
Over The Past 5 Days
Kura Oncology Inc
Profile
Kura Oncology Inc is a biotechnology company that focuses on the discovery and development of precision medicines for the treatment of cancer. Their business model revolves around leveraging their expertise in oncology to identify and design small molecule drug candidates that target specific genetic mutations or biomarkers. Through strategic partnerships and collaborations, Kura aims to advance their drug candidates through clinical studies and ultimately commercialize these precision medicines for patients in need.
Novocure Limited is a medical technology company that focuses on developing and commercializing innovative therapies for cancer treatment. The company's business model revolves around its proprietary treatment platform called tumor treating fields (TTFields), which uses electric fields to disrupt cancer cell division and inhibit tumor growth. Novocure operates by manufacturing and distributing its TTFields delivery system, while also conducting clinical trials and collaborating with healthcare providers to integrate its therapy into standard cancer care.
NextCure Inc is a biopharmaceutical company that operates with a unique business model. They focus on discovering and developing novel immunomedicines to treat various forms of cancer and other immune-related diseases. With a focus on developing innovative therapies that target immune cells, NextCure aims to provide effective and personalized treatment options for patients in need.
Sources:
Blueprint Medicines Corporation’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Blueprint Medicines Corporation versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
